[Effect of recombinant human interleukin 11 on the platelet after hematopoietic stem cell transplantation in patients with leukemia].
OBJECTIVE
To explore the effect and toxicity profile of recombinant human interleukin 11(rhIL-11) on the platelet after hematopoietic stem cell transplantation in patients with leukemia.


METHODS
Twenty-four patients with acute or chronic leukemia treated by allogeneic peripheral blood stem cell transplantation (PBSCT) were randomly divided into a test group and a control group. The patients in the test group were treated with rhIL-11 since the 13th day after PBSCT (1.5mg/d),while the control group were given symptomatic treatment.


RESULTS
The average time for the platelet to recover to the level of 20 x 10(9)/L was 20.8 days in the test group, and 26.0 days in control group respectively, there was significant difference (P<0.01). The average time for the platelet to recover to the level of 50 x 10(9)/L was 25.7 days in the test group, and 32.3 days in the control group respectively, there was also significant difference (P<0.01). The average time for the platelet transfusion was 2.2 in the test group, 4.1 in the control group, and there was significantly different (P<0.01). The average number of megakaryocytes was 12.2 in the test group, 4.8 in the control group on 30th day after the transplantation,and there was significant difference(P<0.01). The main side effects of rhIL-11 were nausea, vomit, debility, headache, dizzy and pain of injection site, and the degree was all Iapproximately II grade.


CONCLUSIONS
rhIL-11 has definite recuperative effect on the recovery of the platelet after PBSCT. There is little side effect, and it can be accepted.
Xu
Ya-jing
YJ
Department of Hematology,Xiangya Hospital,Central South University,Changsha 410008,China. xuyajingdr2004@163.com
Chen
Fang-ping
FP
Li
Xiao-lin
XL
Zhao
Xie-lan
XL
He
Qun
Q
D000293:Adolescent; D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017370:Interleukin-11 / Q000235:genetics / Q000627:therapeutic use*; D007938:Leukemia / Q000097:blood / Q000601:surgery*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000601:surgery; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000188:drug therapy*; D016896:Treatment Outcome
D017370:Interleukin-11; D011994:Recombinant Proteins